Statin intolerance: Why and what to do-with a focus on diabetic people

Current Medicinal Chemistry

Volumn 20, Issue 11, 2013, Pages 1397-1408

  Matteucci, E ^a   Giampietro, O ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adverse Drug Reactions; Cardiovascular Disease; Diabetes Mellitus; Dyslipidemia; Hydroxymethylglutaryl Coa Reductase Inhibitors

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NUTRACEUTICAL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APHERESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; COGNITIVE DEFECT; DIABETES MELLITUS; DIABETIC PATIENT; DIET THERAPY; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INSOMNIA; KIDNEY DYSFUNCTION; LIFESTYLE; LIPOPHILICITY; LIVER TOXICITY; MEDICAL CARE; MENTAL DISEASE; MOOD DISORDER; MUSCLE DISEASE; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; PHYSICAL ACTIVITY; RHABDOMYOLYSIS; SIDE EFFECT; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

ACYL COENZYME A; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84877982021     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320110004     Document Type: Article

References (88)

1. Ginsberg, H.N. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin. Endocrinol. Metab., 2006, 91, 383-392.
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care, 2012, 35, S11-S63.
3. Leiter, L.A.; Lundman, P.; da Silva, P.M.; Drexel, H.; Jünger, C.; Gitt, A.K; DYSIS investigators. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet. Med., 2011, 28, 1343-1351.
4. Zhang, Q.; Zhao, C.; Davies, M.J.; Radican, L.; Seck, T. Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. Am. J. Manag. Care, 2011, 17, 746-752.
5. Alberton, M.; Wu, P.; Druyts, E.; Briel, M.; Mills, E.J. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. Q.J.M., 2012, 105, 145-157.
6. Culver, A.L.; Ockene, I.S.; Balasubramanian, R.; Olendzki, B.C.; Sepavich, D.M.; Wactawski-Wende, J.; Manson, J.E.; Qiao, Y.; Liu, S.; Merriam, P.A.; Rahilly-Tierny, C.; Thomas, F.; Berger, J.S.; Ockene, J.K.; Curb, J.D.; Ma, Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med., 2012, 172, 144-152.
7. Preiss, D.; Seshasai, S.R.; Welsh, P.; Murphy, S.A.; Ho, J.E.; Waters, D.D.; DeMicco, D.A.; Barter, P.; Cannon, C.P.; Sabatine, M.S.; Braunwald, E.; Kastelein, J.J.; de Lemos, J.A.; Blazing, M.A.; Pedersen, T.R.; Tikkanen, M.J.; Sattar, N.; Ray, K.K. Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: a meta-analysis. J.A.M.A., 2011, 305, 2556-2564.
8. Mills, E.J.; Wu, P.; Chong, G.; Ghement, I.; Singh, S.; Akl, E.A.; Eyawo, O.; Guyatt, G.; Berwanger, O.; Briel, M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. Q.J.M., 2011, 104, 109-124.
9. Fernandez, G.; Spatz, E.S.; Jablecki, C.; Phillips, P.S. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve. Clin. J. Med., 2011, 78, 393-403.
10. Bruckert, E.; Hayem, G.; Dejager, S.; Yau, C.; Bégaud. B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO study. Cardiovasc. Drugs Ther., 2005, 19, 403-414.
11. Neuvonen, P J.; Backman, J T.; Niemi, M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet., 2008, 47, 463-474.
12. Mancini, G.B.; Baker, S.; Bergeron, J.; Fitchett, D.; Frohlich, J.; Genest, J.; Gupta, M.; Hegele, R.A.; Ng, D.; Pope, J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can. J. Cardiol., 2011, 27, 635-662.
13. Luvai, A.; Mbagaya, W.; Hall, A.S.; Barth, J.H. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin. Med. Insights Cardiol., 2012, 6, 17-33.
14. Duggan, S.T. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs, 2012, 72, 565-584.
15. Maggo, S.D.; Kennedy, M.A.; Clark, D.W. Clinical implications of pharmacogenetic variations on the effects of statins. Drug Saf., 2011, 34, 1-19.
16. Corsini, A.; Ceska, R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr. Med. Res. Opin., 2011, 27, 1551-1562.
17. While, A.; Keen, L. The effects of statins on mood: a review of the literature. Eur. J. Cardiovasc. Nurs., 2012, 11, 85-96.
18. Rojas-Fernandez, C.H.; Cameron, J.C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann. Pharmacother., 2012, 46, 549-557.
19. Huffman, J.C.; Stern, T.A. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin. Neurosci., 2007, 9, 29-45.
20. Hsia, J.; MacFadyen, J.G.; Monyak, J.; Ridker, P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol., 2011, 57, 1666-1675.
21. Tzefos, M.; Olin, J. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. L. J. Clin. Lipidol., 2011, 5, 450-459.
22. Calderon, R.M.; Cubeddu, L.X.; Goldberg, R.B.; Schiff, E.R. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin. Proc., 2010, 85, 349-356.
23. Brindisi, M.C.; Guiu, B.; Duvillard, L.; Athias, A.; Rollot, F.; Bouillet, B.; Beacco, M.; Hillon, P.; Cercueil, J.P.; Verges, B.; Petit, J.M. Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes. Atherosclerosis, 2012, 224, 465-468.
24. Dostalek, M.; Sam, W.J.; Paryani, K.R.; Macwan, J.S.; Gohh, R.Y.; Akhlaghi, F. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Clin. Pharmacokinet., 2012, 51, 591-606.
25. Padala, S.; Thompson, P.D. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis, 2012, 222, 15-21.
26. Berg, J.M.; Tymoczko, J.L.; Stryer, L. Biochemistry, 5th ed.; W H Freeman: New York, 2002.
27. Cantagrel, V.; Lefeber, D.J. From glycosylation disorders to dolichol biosynthesis defects: a new class of metabolic diseases. J. Inherit. Metab. Dis., 2011, 34, 859-867.
28. Bentinger, M.; Tekle, M.; Dallner, G. Coenzyme Q-biosynthesis and functions. Biochem. Biophys. Res. Commun., 2010, 396, 74-79.
29. Hang, H.C.; Linder, M.E. Exploring protein lipidation with chemical biology. Chem. Rev., 2011, 111, 6341-6358.
30. Rojas, A.M.; Fuentes, G.; Rausell, A.; Valencia, A. The Ras protein superfamily: evolutionary tree and role of conserved amino acids. J. Cell. Biol., 2012, 196, 189-201.
31. Maxfield, F.R.; van Meer, G. Cholesterol, the central lipid of mammalian cells. Curr. Opin. Cell. Biol., 2010, 22, 422-429.
32. George, K.S.; Wu, S. Lipid raft: A floating island of death or survival. Toxicol. Appl. Pharmacol., 2012, 259, 311-319.
33. Savelieva, I.; Kourliouros, A.; Camm. J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn. Schmiedebergs. Arch. Pharmacol., 2010, 381, 1-13.
34. Cibicková, L. Statins and their influence on brain cholesterol. J. Clin. Lipidol., 2011, 5, 373-379.
35. Mailman, T.; Hariharan, M.; Karten, B. Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. J. Neurochem., 2011, 119, 1002-1015.
36. Tsuchiya, M.; Hosaka, M.; Moriguchi, T.; Zhang, S.; Suda, M.; Yokota-Hashimoto, H.; Shinozuka, K.; Takeuchi, T. Cholesterol biosynthesis pathway intermediates and inhibitors regulate glucosestimulated insulin secretion and secretory granule formation in pancreatic beta-cells. Endocrinology, 2010, 151, 4705-4716.
37. Takaguri, A.; Satoh, K.; Itagaki, M.; Tokumitsu, Y.; Ichihara, K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J. Pharmacol. Sci., 2008, 107, 80-89.
38. Marcoff, L.; Thompson, P.D. The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J. Am. Coll. Cardiol., 2007, 49, 2231-2237.
39. Mas, E.; Mori, T.A. Coenzyme Q10 and statin myalgia: what is the evidence? Curr. Atheroscler. Rep., 2010, 12, 407-413.
40. Päivä, H.; Thelen, K.M.; Van Coster, R.; Smet, J.; De Paepe, B.; Mattila, K.M.; Laakso, J.; Lehtimäki, T.; von Bergmann, K.; Lütjohann, D.; Laaksonen, R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther., 2005, 78, 60-68.
41. Sirvent, P.; Fabre, O.; Bordenave, S.; Hillaire-Buys, D.; Raynaud De Mauverger, E.; Lacampagne, A.; Mercier, J. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol. Appl. Pharmacol., 2012, 259, 263-268.
42. Hubal, M.J.; Reich, K.A.; De Biase, A.; Bilbie, C.; Clarkson, P.M.; Hoffman, E.P.; Thompson, P.D. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve., 2011, 44, 393-401.
43. Molyneux, S.L.; Florkowski, C.M.; George, P.M.; Pilbrow, A.P.; Frampton, C.M.; Lever, M.; Richards, A.M. Coenzyme Q10: an independent predictor of mortality in chronic heart failure J. Am. Coll. Cardiol., 2008, 52, 1435-1441.
44. McMurray, J.J.; Dunselman, P.; Wedel, H.; Cleland, J.G.; Lindberg, M.; Hjalmarson, A.; Kjekshus, J.; Waagstein, F.; Apetrei, E.; Barrios, V.; Böhm, M.; Kamensk, G.; Komajda, M.; Mareev, V.; Wikstrand, J.; CORONA Study Group. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J. Am. Coll. Cardiol., 2010, 56, 1196-204.
45. Satoh, K.; Takaguri, A.; Itagaki, M.; Kano, S.; Ichihara, K. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs. J. Pharmacol. Sci., 2008, 106, 593-599.
46. Nadanaciva, S.; Dykens, J.A.; Bernal, A.; Capaldi, R.A.; Will, Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol., 2007, 223, 277-287.
47. Uliná, O.; Vanová, O.; Waczulíková, I.; Boek, P.; Sikurová, L.; Bada, V.; Kucharská, J. Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. Physiol. Res., 2012, 61, 185-193.
48. Kwak, H.B.; Thalacker-Mercer, A.; Anderson, E.J.; Lin, C.T.; Kane, D.A.; Lee, N.S.; Cortright, R.N.; Bamman, M.M.; Neufer, P.D. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic. Biol. Med., 2012, 52, 198-207.
49. Tanaka, S.; Sakamoto, K.; Yamamoto, M.; Mizuno, A.; Ono, T.; Waguri, S.; Kimura, J. Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers. J. Pharmacol. Sci., 2010, 114, 454-563.
50. Mullen, P.J.; Zahno, A.; Lindinger, P.; Maseneni, S.; Felser, A.; Krähenbühl, S.; Brecht. K. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim. Biophys. Acta, 2011, 1813, 2079-2087.
51. Martin, S.B.; Cenini, G.; Barone, E.; Dowling, A.L.; Mancuso, C.; Butterfield, D.A.; Murphy, M.P.; Head, E. Coenzyme Q10 and cognition in atorvastatin treated dogs. Neurosci. Lett., 2011, 501, 92-95.
52. Balakumar, P.; Kathuria, S.; Taneja, G.; Kalra, S.; Mahadevan, N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J. Mol. Cell. Cardiol., 2012, 52, 83-92.
53. Zeki, A.A.; Thai, P.; Kenyon, N.J.; Wu, R. Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells. Respir. Res., 2012, 13, 38.
54. Iwata, A.; Shirai, R.; Ishii, H.; Kushima, H.; Otani, S.; Hashinaga, K.; Umeki, K.; Kishi, K.; Tokimatsu, I.; Hiramatsu, K.; Kadota, J. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin. Exp. Immunol., 2012, 168, 234-240.
55. Gu, M.X.; Fu, Y.; Sun, X.L.; Ding, Y.Z.; Li, C.H.; Pang, W.; Pan, S.; Zhu, Y. Proteomic analysis of endothelial lipid rafts reveals a novel role of statins in antioxidation. J. Proteome Res., 2012, 11, 2365-2373.
56. Bouitbir, J.; Charles, A.L.; Echaniz-Laguna, A.; Kindo, M.; Daussin, F.; Auwerx, J.; Piquard, F.; Geny, B.; Zoll, J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur. Heart J., 2012, 33, 1397-1407.
57. Dunn, S.E.; Youssef, S.; Goldstein, M.J.; Prod'homme, T.; Weber, M.S.; Zamvil, S.S.; Steinman, L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med., 2006, 203, 401-412.
58. Li, X.L.; Dou, Y.C.; Liu, Y.; Shi, C.W.; Cao, L.L.; Zhang, X.Q.; Zhu, J.; Duan, R.S. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell. Immunol., 2011, 271, 455-461.
59. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 2001, 7, 687-692.
60. Kim, Y.C.; Kim, K.K.; Shevach, E.M. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factorbeta signal transduction. Immunology, 2010, 130, 484-493.
61. Link A, Selejan S, Hewera L, Walter F, Nickenig G, Böhm M. Rosuvastaton induces apoptosis in CD4+CD28null T cells in patients with acute coronary syndrome. Clin. Res. Cardiol., 2011, 100, 147-158.
62. Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins. Oncogene, 2012, doi: 10.1038/onc.2012.6.
63. Garcia-Ruiz, C.; Morales, A.; Fernandez-Checa, J.C. Statins and protein prenylation in cancer cell biology and therapy. Anticancer Agents Med. Chem., 2012, 12, 303-315.
64. Kim, K. Statin and cancer risks: from tasseomancy of epidemiologic studies to meta-analyses. J. Clin. Oncol., 2006, 24, 4796-4797.
65. Menter, D.G.; Ramsauer, V.P.; Harirforoosh, S.; Chakraborty, K.; Yang, P.; His, L.; Newman, R.A.; Krishnan, K. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PloS. One, 2011, 6, e28813.
66. Lee, B.J.; Lee, H.S.; Kim, C.D.; Jung, S.W.; Seo, Y.S.; Kim, Y.S.; Jeen, Y.T.; Chun, H.J.; Um, S.H.; Lee, S.W.; Choi, J.H.; Ryu, H.S. The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPAR Agonist on the Activation of Rat Pancreatic Stellate Cells Gut. Liver, 2012, 6, 262-269.
67. Sokalska, A.; Cress, A.; Bruner-Tran, K.L.; Osteen, K.G.; Taylor, H.S.; Ortega, I.; Duleba, A.J. Simvastatin Decreases Invasiveness of Human Endometrial Stromal Cells. Biol. Reprod., 2012, doi: 10.1095/ biolreprod.111.098806.
68. Olivieri, F.; Mazzanti, I.; Abbatecola, A.M.; Recchioni, R.; Marcheselli, F.; Procopio, A.D.; Antonicelli, R. Telomere/ Telomerase system: a new target of statins pleiotropic effect? Curr. Vasc. Pharmacol., 2012, 10, 216-224.
69. Shi, Z.; Ruvkun, G. The mevalonate pathway regulates microRNA activity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 4568-4573.
70. Yamakuchi, M. MicroRNA Regulation of SIRT1. Front. Physiol., 2012, 3, 68.
71. Vandenberg, B.F.; Robinson, J. Management of the patient with statin intolerance. Curr. Atheroscler. Rep., 2010, 12, 48-57.
72. Eckel, R.H. Approach to the patient who is intolerant of statin therapy. J. Clin. Endocrinol. Metab., 2010, 95, 2015-2022.
73. Sikka, P.; Kapoor, S.; Bindra, V.K.; Sharma, M.; Vishwakarma, P.; Saxena, K.K. Statin intolerance: now a solved problem. J. Postgrad. Med., 2011, 57, 321-328.
74. Pasternak, R.C.; Smith, S.C. Jr.; Bairey-Merz, C.N.; Grundy, S.M.; Cleeman, J.I.; Lenfant, C.; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 2002, 106, 1024-1028.
75. McKenney, J.M.; Davidson, M.H.; Jacobson, T.A.; Guyton, J.R; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol., 2006, 97, 89C-94C.
76. Arca, M.; Pigna, G. Treating statin-intolerant patients. Diabetes. Metab. Syndr. Obes., 2011, 4, 155-166.
77. Schaars, C.F.; Stalenhoef, A.F. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr. Opin. Lipidol., 2008, 19, 553-557.
78. Muraki, A.; Miyashita, K.; Mitsuishi, M.; Tamaki, M.; Tanaka, K.; Itoh, H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J. Appl. Physiol., 2012, doi: 10.1152/japplphysiol.01362.2011.
79. Reinhart, K.M.; Woods, J.A. Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am. J. Health. Syst. Pharm., 2012, 69, 291-300.
80. Ahmed, W.; Khan, N.; Glueck, C.J.; Pandey, S.; Wang, P.; Goldenberg, N.; Uppal, M.; Khanal, S. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositismyalgia in statin-treated patients. Transl. Res., 2009, 153, 11-16.
81. Glueck, C.J.; Abuchaibe, C.; Wang, P. Symptomatic myositismyalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med. Hypotheses., 2011, 77, 658-661.
82. Lee, J.H.; O'Keefe, J.H.; Bell, D.; Hensrud, D.D.; Holick, M.F. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J. Am. Coll. Cardiol., 2008, 52, 1949-1956.
83. Gordon, R.Y.; Cooperman, T.; Obermeyer, W.; Becker, D.J. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch. Intern. Med., 2010, 170, 1722-1727.
84. Singh, I.M.; Shishehbor, M.H.; Ansell, B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA, 2007, 298, 786-798.
85. Lim, S.; Park, Y.M.; Sakuma, I.; Koh, K.K. How to control residual cardiovascular risk despite statin treatment: Focusing on HDLcholesterol. Int. J. Cardiol., 2012, doi:10.1016/j.ijcard.2012. 03.127.
86. Rubins, H.B.; Robins, S.J.; Collins, D.; Fye, C.L.; Anderson, J.W.; Elam, M.B.; Faas, F.H.; Linares, E.; Schaefer, E.J.; Schectman, G.; Wilt, T.J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341, 410-418.
87. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesäniemi, Y.A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366, 1849-1861.
88. Maningat, P.; Breslow, J.L. Needed: pragmatic clinical trials for statin-intolerant patients. N. Engl. J. Med., 2011, 365, 2250-2251.